Publication date: Jul 26, 2024
Individual-based models of infectious disease dynamics commonly use network structures to represent human interactions. Network structures can vary in complexity, from single-layered with homogeneous mixing to multi-layered with clustering and layer-specific contact weights. Here we assessed policy-relevant consequences of network choice by simulating different network structures within an established individual-based model of SARS-CoV-2 dynamics. We determined the clustering coefficient of each network structure and compared this to several epidemiological outcomes, such as cumulative and peak infections. High-clustered networks estimate fewer cumulative infections and peak infections than less-clustered networks when transmission probabilities are equal. However, by altering transmission probabilities, we find that high-clustered networks can essentially recover the dynamics of low-clustered networks. We further assessed the effect of workplace closures as a layer-targeted intervention on epidemiological outcomes and found in this scenario a single-layered network provides a sufficient approximation of intervention effect relative to a multi-layered network when layer-specific contact weightings are equal. Overall, network structure choice within models should consider the knowledge of contact weights in different environments and pathogen mode of transmission to avoid over- or under-estimating disease burden and impact of interventions.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | intervention |
disease | MESH | COVID-19 |
disease | MESH | infectious disease |
pathway | REACTOME | Infectious disease |
disease | MESH | infections |
drug | DRUGBANK | Aspartame |
disease | IDO | pathogen |
drug | DRUGBANK | Coenzyme M |
disease | IDO | pathogen host |
disease | VO | population |
disease | VO | Gap |
disease | VO | injection |
disease | VO | vaccination |
disease | IDO | infection |
disease | MESH | reinfection |
disease | VO | time |
disease | IDO | process |
disease | IDO | facility |
disease | VO | effective |
disease | MESH | uncertainty |
disease | MESH | influenza |
disease | VO | Respiratory syncytial virus |
drug | DRUGBANK | Nevirapine |
disease | VO | effectiveness |
drug | DRUGBANK | Etoperidone |
disease | IDO | infectivity |
drug | DRUGBANK | Serine |
disease | IDO | contact tracing |
disease | IDO | susceptibility |
disease | VO | USA |
disease | VO | syringe |
disease | IDO | immunodeficiency |
disease | VO | vaccine |
disease | VO | frequency |